Status:
COMPLETED
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
Brief Summary
To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.
Eligibility Criteria
Inclusion
- Malignant solid tumor with no currently approved treatment
- Adequate functions Bone Marrow, Renal, Liver and Cardiac
Exclusion
- Any surgery, radiotherapy within 4 weeks of baseline disease assessments
- Clinically significant abnormalities of the cornea
- Patients with symptomatic brain/central nerve system metastases
- Any clinically significant gastrointestinal abnormalities
- Uncontrolled or significant cardiovascular disease
- Patients with significant interstitial pneumonia or pulmonary fibrosis
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00783328
Start Date
November 1 2008
End Date
March 1 2011
Last Update
June 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sunto-gun, Shizuoka, Japan